Skip to main content

Table 1 Demographic, clinical, and biological characteristics of 1491 patients not intubated on the day of intensive care unit (ICU) admission, according to oxygenation strategy

From: Benefits and risks of noninvasive oxygenation strategy in COVID-19: a multicenter, prospective cohort study (COVID-ICU) in 137 hospitals

 

No

All patients

Standard oxygen

HFNC

NIV

P value

(n = 1491)

(n = 766)

(n = 567)

(n = 158)

Age, years

1491

63 (54–71)

61 (53–70)

64 (55–72)

65 (56–72)

0.005

Women, n (%)

1488

397 (27)

212 (28)

140 (25)

45 (29)

0.389

Body mass index, kg/m2

1370

28 (25–31)

28 (25–32)

28 (25–31)

29 (26–33)

0.334

 ≥ 30 kg/m2, n (%)

1370

504 (37)

260 (37)

179 (35)

65 (45)

0.085

Active smokers, n (%)

1465

67 (5)

35 (5)

19 (4)

13 (8)

0.037

SAPS II score

1398

30 (23–37)

27 (21–35)

32 (27–39)

33 (26–41)

 < 0.001

SOFA score at ICU admission

1290

3 (2–4)

2 (2–4)

3 (2–4)

3 (2–5)

 < 0.001

Treated hypertension, n (%)

1485

687 (46)

331 (43)

263 (47)

93 (59)

0.001

Known diabetes, n (%)

1486

409 (28)

206 (27)

145 (26)

58 (37)

0.018

Immunodeficiencya, n (%)

1479

102 (7)

42 (6)

48 (9)

12 (8)

0.090

Clinical frailty scale

1379

2 (2–3)

2 (1–3)

2 (2–3)

2 (2–4)

 < 0.001

Time between first symptoms and ICU admission, days

1435

9 (6–12)

8 (6–11)

9 (7–12)

9 (7–12)

 < 0.001

During the first 24 h in ICU

Hemodynamic component of the SOFA

1435

0 (0–0)

0 (0–0)

0 (0–0)

0 (0–0)

0.351

Renal component of the SOFA

1416

0 (0–0)

0 (0–0)

0 (0–0)

0 (0–0)

0.047

Corticosteroidsb, n (%)

1476

165 (11)

50 (7)

85 (15)

30 (19)

 < 0.001

Blood gases

 pH

1365

7.46 (7.42–7.48)

7.45 (7.42–7.48)

7.46 (7.44–7.49)

7.44 (7.41–7.48)

 < 0.001

 PaCO2, mmHg

1367

36 (32–40)

36 (33–40)

36 (32–39)

36 (32–43)

0.039

 PaO2/FiO2c

1216

122 (82–177)

154 (89–219)

104 (77–134)

128 (86–169)

 < 0.001

 HCO3, mmol/L

1357

25 (23–27)

25 (23–27)

25 (23–27)

25 (23–28)

0.769

 Lactate, mmol/L

1281

1.1 (0.9–1.5)

1.1 (0.8–1.5)

1.2 (0.9–1.5)

1.1 (0.9–1.5)

0.039

Biology

 Lymphocyte count, × 109/L

1199

0.8 (0.6–1.2)

0.9 (0.6–1.2)

0.8 (0.6–1.1)

0.8 (0.6–1.1)

0.016

 Platelet count, × 109/L

1342

222 (167–289)

205 (159–275)

236 (177–302)

241 (177–294)

 < 0.001

 Total bilirubin, µmol/L

1023

9 (7–12)

9 (7–12)

9 (7–12)

9 (7–13)

0.085

 Serum creatinine, µmol/L

1369

71 (59–94)

72 (60–91)

71 (57–92)

74 (59–110)

0.098

 D–dimers, µg/L

548

1159 (647–2204)

1080 (675–2000)

1282 (708–2930)

1040 (538–1939)

0.097

Period of admission

1491

    

 < 0.001

February 25 to March 28, 2020, n (%)

 

713 (48)

479 (63)

187 (33)

47 (30)

 

March 29 to May 4, 2020, n (%)

 

778 (52)

287 (37)

380 (67)

111 (70)

 

Do-not-intubate, n (%)

1491

155 (10%)

65 (8%)

54 (10%)

36 (23%)

 < 0.001

  1. Results are expressed as n (%) or median (25th–75th percentiles)
  2. HFNC high-flow nasal cannula, NIV noninvasive ventilation, SAPS simplified acute physiology score, SOFA sequential organ failure assessment, PaCO2 partial pressure of carbon dioxide, PaO2/FiO2 partial pressure of oxygen to fraction of inspired oxygen ratio, HCO3 bicarbonate
  3. aDefined as hematological malignancies, active solid tumor, or having received specific anti-tumor treatment within a year, solid organ transplant, human immunodeficiency virus, or immunosuppressants
  4. bIrrespective of the dose and the indication
  5. cCalculated for all patients, including those on oxygen therapy by using conversion tables provided in the online supplement